Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159101 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL5909104 | 0.88 | CHRNB2 (0.48) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL62434 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL86929 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL26650248 | 0.84 | CHRNB2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL26650243 | 0.84 | CHRNB2 (0.50) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL15087605 | 0.82 | BTK (0.45) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL10137131 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL595590 | 0.80 | BTK (0.49) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL17099599 | 0.80 | BTK (0.49) | SMN1; SMN2CHRNB2CHRNA4CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2472319-B1 | Titanium black dispersion composition for a solid state imaging element, black radiation-sensitive composition containing the same, use of the composition for forming a black cured film, method of producing a black cured film | FUJIFILM CORP (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-2472319-A2 | Titanium black dispersion composition, black radiation-sensitive composition containing the same, black cured film, solid state imaging element and method for producing a black cured film | Fujifilm Corporation (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | SMN1; SMN2 4000/4885CHRNB2 2173/4885CHRNA4 1832/4885 |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | SMN1; SMN2 4000/4885CHRNB2 2173/4885CHRNA4 1832/4885 |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | SMN1; SMN2 4000/4885CHRNB2 2173/4885CHRNA4 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.